Options mapped

Thymic carcinoma / thymoma: options by country

Sourced options by country plus visit-prep questions for Thymic carcinoma / thymoma. Each line links to its regulator, HTA, or guideline source. This page maps options; it does not recommend or rank them.

Options mappedSolid tumorLast checked June 2026

What this page does

Maps options by country

It maps sourced options by country alongside diagnosis wording, stage, test results, specialists, and trial-search terms.

What it does not do

Does not choose treatment

It does not rank treatments, recommend a choice, or decide clinical fit.

Where it comes from

Built on trusted sources

Every option links to a trusted regulator, HTA, or guideline source, and the list grows as new sources pass verification.

Information to gather before the next visit

Is the tumor thymoma, B3 thymoma, or thymic carcinoma?
Is the disease resectable, borderline resectable, inoperable, metastatic, or recurrent?
Are systemic options being used as standard chemotherapy, off-label targeted therapy, or clinical trial treatment?
Is the diagnosis unresectable thymic carcinoma rather than thymoma?

Trial-search terms to discuss

Thymic carcinoma / thymoma clinical trial

Options by country

Treatments by country

Regulatory and access status by country, from official sources. It shows what exists and where — not a recommendation.

Japan

Lenvatinib mesylate (Lenvima)[1]ApprovedNo biomarker requirement stated in fetched Japan approval news release; Unresectable thymic carcinoma; supporting REMORA context involved advanced/metastatic thymic carcinoma after at least one prior platinum-based regimen. · Company/regulatory news release is not a PMDA label page; exact PMDA label, reimbursement, and current local access should be checked. No claim made for thymoma or for countries outside Japan. Confidence/conflicts: Medium-high for Japan approval announcement; exact PMDA label source remains a follow-up gap.

Sources

Eisai Co., Ltd. / MSD K.K. — company regulatory approval news release · company regulatory approval news release

This is official regulatory and access status only — not medical advice, not a recommendation, and not a statement about eligibility. Whether any option fits depends on your situation and your oncology team. Status changes over time; confirm the current position with the linked source. Last checked 2026-06-12.

Beyond approved care

In clinical trials & emerging options

Options that are not — or not yet — an approved standard where you live: studies, clinical trials, off-label use, and early evidence that your own oncologist may not raise. Each is labeled by how strong the evidence is. A listing here is information to research and discuss with your team; it does not mean a treatment is proven, safe for you, or available today.

In clinical trials

Surgery; postoperative radiation therapy; induction chemotherapy; chemoradiation; platinum-based chemotherapy regimens; biological therapies including octreotide/prednisone, sunitinib, everolimus, lenvatinib; pembrolizumab under clinical evaluation; clinical trialsClinical trialClinical trialInvestigationalUnited States · No biomarker required by fetched NCI PDQ framework; Early-stage, locally advanced, inoperable, metastatic, and recurrent thymoma/thymic carcinoma contexts. · NCI PDQ is an evidence summary, not a payer/regulator source. Many systemic options are based on small studies in rare tumors and are not automatically approved or available for thymic epithelial tumors. Confidence/conflicts: High for U.S. evidence-summary framework; regulator-specific approvals need separate verification. National Cancer Institute (NCI) — national cancer agency evidence summary
Surgery; postoperative radiation therapy; induction chemotherapy; chemoradiation; platinum-based chemotherapy regimens; biological therapies including octreotide/prednisone, sunitinib, everolimus, lenvatinib; pembrolizumab under clinical evaluation; clinical trialsClinical trialClinical trialInvestigationalUnited States · No biomarker required by fetched NCI PDQ framework; Early-stage, locally advanced, inoperable, metastatic, and recurrent thymoma/thymic carcinoma contexts. · NCI PDQ is an evidence summary, not a payer/regulator source. Many systemic options are based on small studies in rare tumors and are not automatically approved or available for thymic epithelial tumors. Confidence/conflicts: High for U.S. evidence-summary framework; regulator-specific approvals need separate verification. National Cancer Institute (NCI) — national cancer agency evidence summary
Surgery; postoperative radiation therapy; induction chemotherapy; chemoradiation; platinum-based chemotherapy regimens; biological therapies including octreotide/prednisone, sunitinib, everolimus, lenvatinib; pembrolizumab under clinical evaluation; clinical trialsClinical trialClinical trialInvestigationalUnited States · No biomarker required by fetched NCI PDQ framework; Early-stage, locally advanced, inoperable, metastatic, and recurrent thymoma/thymic carcinoma contexts. · NCI PDQ is an evidence summary, not a payer/regulator source. Many systemic options are based on small studies in rare tumors and are not automatically approved or available for thymic epithelial tumors. Confidence/conflicts: High for U.S. evidence-summary framework; regulator-specific approvals need separate verification. National Cancer Institute (NCI) — national cancer agency evidence summary
Surgery; postoperative radiation therapy; induction chemotherapy; chemoradiation; platinum-based chemotherapy regimens; biological therapies including octreotide/prednisone, sunitinib, everolimus, lenvatinib; pembrolizumab under clinical evaluation; clinical trialsClinical trialClinical trialInvestigationalUnited States · No biomarker required by fetched NCI PDQ framework; Early-stage, locally advanced, inoperable, metastatic, and recurrent thymoma/thymic carcinoma contexts. · NCI PDQ is an evidence summary, not a payer/regulator source. Many systemic options are based on small studies in rare tumors and are not automatically approved or available for thymic epithelial tumors. Confidence/conflicts: High for U.S. evidence-summary framework; regulator-specific approvals need separate verification. National Cancer Institute (NCI) — national cancer agency evidence summary
Surgery; postoperative radiation therapy; induction chemotherapy; chemoradiation; platinum-based chemotherapy regimens; biological therapies including octreotide/prednisone, sunitinib, everolimus, lenvatinib; pembrolizumab under clinical evaluation; clinical trialsClinical trialClinical trialInvestigationalUnited States · No biomarker required by fetched NCI PDQ framework; Early-stage, locally advanced, inoperable, metastatic, and recurrent thymoma/thymic carcinoma contexts. · NCI PDQ is an evidence summary, not a payer/regulator source. Many systemic options are based on small studies in rare tumors and are not automatically approved or available for thymic epithelial tumors. Confidence/conflicts: High for U.S. evidence-summary framework; regulator-specific approvals need separate verification. National Cancer Institute (NCI) — national cancer agency evidence summary
Surgery; postoperative radiation therapy; induction chemotherapy; chemoradiation; platinum-based chemotherapy regimens; biological therapies including octreotide/prednisone, sunitinib, everolimus, lenvatinib; pembrolizumab under clinical evaluation; clinical trialsClinical trialClinical trialInvestigationalUnited States · No biomarker required by fetched NCI PDQ framework; Early-stage, locally advanced, inoperable, metastatic, and recurrent thymoma/thymic carcinoma contexts. · NCI PDQ is an evidence summary, not a payer/regulator source. Many systemic options are based on small studies in rare tumors and are not automatically approved or available for thymic epithelial tumors. Confidence/conflicts: High for U.S. evidence-summary framework; regulator-specific approvals need separate verification. National Cancer Institute (NCI) — national cancer agency evidence summary
Pembrolizumab (MK-3475) plus lenvatinib, carboplatin, and paclitaxel; KFA115 alone or with pembrolizumabClinical trial · NCT05832827Clinical trialTrial only (registry)Japan · No thymic carcinoma biomarker requirement stated in fetched registry records; First-line for previously untreated advanced or recurrent thymic carcinoma in NCT05832827; selected advanced cancers including thymic carcinoma in NCT05544929. · Registry records do not establish PMDA approval, reimbursement, routine availability, active enrollment beyond the stated status, or individual eligibility. NCT05544929 is a broad cohort rather than thymic carcinoma-only. Confidence/conflicts: High for Japan registry-listed trial activity; local approval/access status unverified. ClinicalTrials.gov — clinical-trial registry
Pembrolizumab (MK-3475) plus lenvatinib, carboplatin, and paclitaxel; KFA115 alone or with pembrolizumabClinical trial · NCT05832827Clinical trialTrial only (registry)Japan · No thymic carcinoma biomarker requirement stated in fetched registry records; First-line for previously untreated advanced or recurrent thymic carcinoma in NCT05832827; selected advanced cancers including thymic carcinoma in NCT05544929. · Registry records do not establish PMDA approval, reimbursement, routine availability, active enrollment beyond the stated status, or individual eligibility. NCT05544929 is a broad cohort rather than thymic carcinoma-only. Confidence/conflicts: High for Japan registry-listed trial activity; local approval/access status unverified. ClinicalTrials.gov — clinical-trial registry
Pembrolizumab (MK-3475) plus lenvatinib, carboplatin, and paclitaxel; KFA115 alone or with pembrolizumabClinical trial · NCT05832827Clinical trialTrial only (registry)Japan · No thymic carcinoma biomarker requirement stated in fetched registry records; First-line for previously untreated advanced or recurrent thymic carcinoma in NCT05832827; selected advanced cancers including thymic carcinoma in NCT05544929. · Registry records do not establish PMDA approval, reimbursement, routine availability, active enrollment beyond the stated status, or individual eligibility. NCT05544929 is a broad cohort rather than thymic carcinoma-only. Confidence/conflicts: High for Japan registry-listed trial activity; local approval/access status unverified. ClinicalTrials.gov — clinical-trial registry
Pembrolizumab (MK-3475) plus lenvatinib, carboplatin, and paclitaxel; KFA115 alone or with pembrolizumabClinical trial · NCT05832827Clinical trialTrial only (registry)Japan · No thymic carcinoma biomarker requirement stated in fetched registry records; First-line for previously untreated advanced or recurrent thymic carcinoma in NCT05832827; selected advanced cancers including thymic carcinoma in NCT05544929. · Registry records do not establish PMDA approval, reimbursement, routine availability, active enrollment beyond the stated status, or individual eligibility. NCT05544929 is a broad cohort rather than thymic carcinoma-only. Confidence/conflicts: High for Japan registry-listed trial activity; local approval/access status unverified. ClinicalTrials.gov — clinical-trial registry
Sunitinib; palbociclib; paclitaxel plus cisplatin; neoadjuvant docetaxel/cisplatin; KFA115 with pembrolizumab; anetumab ravtansine with cisplatin/gemcitabine broad solid-tumor contextClinical trial · NCT02623127Clinical trialTrial only (registry)Korea · No biomarker requirement stated in fetched Korea registry records; Metastatic or recurrent thymic carcinoma; recurrent or refractory advanced thymic epithelial tumor; locally advanced stage III or IV thymic cancer; broad selected advanced cancers including thymic carcinoma. · Several Korea records are completed, terminated, or unknown status and do not imply current access. The broad-cohort studies do not prove thymic carcinoma-specific enrollment at every listed site. Registry records do not establish MFDS approval, reimbursement, or standard-of-care use. Confidence/conflicts: Medium-high for Korea registry-listed trial activity; current treatment access and regulator status remain unverified. ClinicalTrials.gov — clinical-trial registry
Sunitinib; palbociclib; paclitaxel plus cisplatin; neoadjuvant docetaxel/cisplatin; KFA115 with pembrolizumab; anetumab ravtansine with cisplatin/gemcitabine broad solid-tumor contextClinical trial · NCT02623127Clinical trialTrial only (registry)Korea · No biomarker requirement stated in fetched Korea registry records; Metastatic or recurrent thymic carcinoma; recurrent or refractory advanced thymic epithelial tumor; locally advanced stage III or IV thymic cancer; broad selected advanced cancers including thymic carcinoma. · Several Korea records are completed, terminated, or unknown status and do not imply current access. The broad-cohort studies do not prove thymic carcinoma-specific enrollment at every listed site. Registry records do not establish MFDS approval, reimbursement, or standard-of-care use. Confidence/conflicts: Medium-high for Korea registry-listed trial activity; current treatment access and regulator status remain unverified. ClinicalTrials.gov — clinical-trial registry
Sunitinib; palbociclib; paclitaxel plus cisplatin; neoadjuvant docetaxel/cisplatin; KFA115 with pembrolizumab; anetumab ravtansine with cisplatin/gemcitabine broad solid-tumor contextClinical trial · NCT02623127Clinical trialTrial only (registry)Korea · No biomarker requirement stated in fetched Korea registry records; Metastatic or recurrent thymic carcinoma; recurrent or refractory advanced thymic epithelial tumor; locally advanced stage III or IV thymic cancer; broad selected advanced cancers including thymic carcinoma. · Several Korea records are completed, terminated, or unknown status and do not imply current access. The broad-cohort studies do not prove thymic carcinoma-specific enrollment at every listed site. Registry records do not establish MFDS approval, reimbursement, or standard-of-care use. Confidence/conflicts: Medium-high for Korea registry-listed trial activity; current treatment access and regulator status remain unverified. ClinicalTrials.gov — clinical-trial registry
Sunitinib; palbociclib; paclitaxel plus cisplatin; neoadjuvant docetaxel/cisplatin; KFA115 with pembrolizumab; anetumab ravtansine with cisplatin/gemcitabine broad solid-tumor contextClinical trial · NCT02623127Clinical trialTrial only (registry)Korea · No biomarker requirement stated in fetched Korea registry records; Metastatic or recurrent thymic carcinoma; recurrent or refractory advanced thymic epithelial tumor; locally advanced stage III or IV thymic cancer; broad selected advanced cancers including thymic carcinoma. · Several Korea records are completed, terminated, or unknown status and do not imply current access. The broad-cohort studies do not prove thymic carcinoma-specific enrollment at every listed site. Registry records do not establish MFDS approval, reimbursement, or standard-of-care use. Confidence/conflicts: Medium-high for Korea registry-listed trial activity; current treatment access and regulator status remain unverified. ClinicalTrials.gov — clinical-trial registry
CD70-targeted CAR-T cells; target-selected CAR-NK cells with lymphodepletion; pembrolizumab plus chemotherapy; sacituzumab tirumotecan; tislelizumab plus anlotinib; postoperative proton radiotherapy plus platinum-based chemotherapy context; adjuvant radiotherapy; neoadjuvant CAP or nab-paclitaxel/carboplatinClinical trial · NCT07181720Clinical trialTrial only (registry)China · CD70-positive status for the CD70 CAR-T advanced solid tumor study; CD30, CD5, or mesothelin target selection for the CAR-NK study; no biomarker stated for other fetched China records; CD70-positive advanced solid tumor including thymic carcinoma; relapsed/refractory B2 thymoma or thymic carcinoma; locally advanced or metastatic thymic carcinoma; second-line thymoma/thymic carcinoma; postoperative thymus tumor radiotherapy; stage II/III thymoma after complete resection; potentially resectable locally advanced thymic epithelial tumors. · Registry records do not establish NMPA approval, reimbursement, routine access, active enrollment for every study, or individual eligibility. Some studies are not yet recruiting or have unknown status, and broad solid-tumor studies require biomarker or protocol-specific confirmation. Confidence/conflicts: High for China registry-listed thymic epithelial tumor trial activity; NMPA approval/routine access not established. ClinicalTrials.gov — clinical-trial registry
CD70-targeted CAR-T cells; target-selected CAR-NK cells with lymphodepletion; pembrolizumab plus chemotherapy; sacituzumab tirumotecan; tislelizumab plus anlotinib; postoperative proton radiotherapy plus platinum-based chemotherapy context; adjuvant radiotherapy; neoadjuvant CAP or nab-paclitaxel/carboplatinClinical trial · NCT07181720Clinical trialTrial only (registry)China · CD70-positive status for the CD70 CAR-T advanced solid tumor study; CD30, CD5, or mesothelin target selection for the CAR-NK study; no biomarker stated for other fetched China records; CD70-positive advanced solid tumor including thymic carcinoma; relapsed/refractory B2 thymoma or thymic carcinoma; locally advanced or metastatic thymic carcinoma; second-line thymoma/thymic carcinoma; postoperative thymus tumor radiotherapy; stage II/III thymoma after complete resection; potentially resectable locally advanced thymic epithelial tumors. · Registry records do not establish NMPA approval, reimbursement, routine access, active enrollment for every study, or individual eligibility. Some studies are not yet recruiting or have unknown status, and broad solid-tumor studies require biomarker or protocol-specific confirmation. Confidence/conflicts: High for China registry-listed thymic epithelial tumor trial activity; NMPA approval/routine access not established. ClinicalTrials.gov — clinical-trial registry
CD70-targeted CAR-T cells; target-selected CAR-NK cells with lymphodepletion; pembrolizumab plus chemotherapy; sacituzumab tirumotecan; tislelizumab plus anlotinib; postoperative proton radiotherapy plus platinum-based chemotherapy context; adjuvant radiotherapy; neoadjuvant CAP or nab-paclitaxel/carboplatinClinical trial · NCT07181720Clinical trialTrial only (registry)China · CD70-positive status for the CD70 CAR-T advanced solid tumor study; CD30, CD5, or mesothelin target selection for the CAR-NK study; no biomarker stated for other fetched China records; CD70-positive advanced solid tumor including thymic carcinoma; relapsed/refractory B2 thymoma or thymic carcinoma; locally advanced or metastatic thymic carcinoma; second-line thymoma/thymic carcinoma; postoperative thymus tumor radiotherapy; stage II/III thymoma after complete resection; potentially resectable locally advanced thymic epithelial tumors. · Registry records do not establish NMPA approval, reimbursement, routine access, active enrollment for every study, or individual eligibility. Some studies are not yet recruiting or have unknown status, and broad solid-tumor studies require biomarker or protocol-specific confirmation. Confidence/conflicts: High for China registry-listed thymic epithelial tumor trial activity; NMPA approval/routine access not established. ClinicalTrials.gov — clinical-trial registry
CD70-targeted CAR-T cells; target-selected CAR-NK cells with lymphodepletion; pembrolizumab plus chemotherapy; sacituzumab tirumotecan; tislelizumab plus anlotinib; postoperative proton radiotherapy plus platinum-based chemotherapy context; adjuvant radiotherapy; neoadjuvant CAP or nab-paclitaxel/carboplatinClinical trial · NCT07181720Clinical trialTrial only (registry)China · CD70-positive status for the CD70 CAR-T advanced solid tumor study; CD30, CD5, or mesothelin target selection for the CAR-NK study; no biomarker stated for other fetched China records; CD70-positive advanced solid tumor including thymic carcinoma; relapsed/refractory B2 thymoma or thymic carcinoma; locally advanced or metastatic thymic carcinoma; second-line thymoma/thymic carcinoma; postoperative thymus tumor radiotherapy; stage II/III thymoma after complete resection; potentially resectable locally advanced thymic epithelial tumors. · Registry records do not establish NMPA approval, reimbursement, routine access, active enrollment for every study, or individual eligibility. Some studies are not yet recruiting or have unknown status, and broad solid-tumor studies require biomarker or protocol-specific confirmation. Confidence/conflicts: High for China registry-listed thymic epithelial tumor trial activity; NMPA approval/routine access not established. ClinicalTrials.gov — clinical-trial registry
CD70-targeted CAR-T cells; target-selected CAR-NK cells with lymphodepletion; pembrolizumab plus chemotherapy; sacituzumab tirumotecan; tislelizumab plus anlotinib; postoperative proton radiotherapy plus platinum-based chemotherapy context; adjuvant radiotherapy; neoadjuvant CAP or nab-paclitaxel/carboplatinClinical trial · NCT07181720Clinical trialTrial only (registry)China · CD70-positive status for the CD70 CAR-T advanced solid tumor study; CD30, CD5, or mesothelin target selection for the CAR-NK study; no biomarker stated for other fetched China records; CD70-positive advanced solid tumor including thymic carcinoma; relapsed/refractory B2 thymoma or thymic carcinoma; locally advanced or metastatic thymic carcinoma; second-line thymoma/thymic carcinoma; postoperative thymus tumor radiotherapy; stage II/III thymoma after complete resection; potentially resectable locally advanced thymic epithelial tumors. · Registry records do not establish NMPA approval, reimbursement, routine access, active enrollment for every study, or individual eligibility. Some studies are not yet recruiting or have unknown status, and broad solid-tumor studies require biomarker or protocol-specific confirmation. Confidence/conflicts: High for China registry-listed thymic epithelial tumor trial activity; NMPA approval/routine access not established. ClinicalTrials.gov — clinical-trial registry
CD70-targeted CAR-T cells; target-selected CAR-NK cells with lymphodepletion; pembrolizumab plus chemotherapy; sacituzumab tirumotecan; tislelizumab plus anlotinib; postoperative proton radiotherapy plus platinum-based chemotherapy context; adjuvant radiotherapy; neoadjuvant CAP or nab-paclitaxel/carboplatinClinical trial · NCT07181720Clinical trialTrial only (registry)China · CD70-positive status for the CD70 CAR-T advanced solid tumor study; CD30, CD5, or mesothelin target selection for the CAR-NK study; no biomarker stated for other fetched China records; CD70-positive advanced solid tumor including thymic carcinoma; relapsed/refractory B2 thymoma or thymic carcinoma; locally advanced or metastatic thymic carcinoma; second-line thymoma/thymic carcinoma; postoperative thymus tumor radiotherapy; stage II/III thymoma after complete resection; potentially resectable locally advanced thymic epithelial tumors. · Registry records do not establish NMPA approval, reimbursement, routine access, active enrollment for every study, or individual eligibility. Some studies are not yet recruiting or have unknown status, and broad solid-tumor studies require biomarker or protocol-specific confirmation. Confidence/conflicts: High for China registry-listed thymic epithelial tumor trial activity; NMPA approval/routine access not established. ClinicalTrials.gov — clinical-trial registry

A clinical-trial listing or early report shows an option is being studied — not that it works, that it is safe for any one person, or that a site is enrolling today. Whether any of these fits is a conversation for your oncology team and the trial team. Last checked 2026-06-12.